Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
$0.75
-6.9%
$0.98
$7.91
$744.00
$4.37M2.5858,707 shs602,369 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.52
-1.9%
$3.21
$1.75
$8.62
$5.90M1.33798,935 shs50,838 shs
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
$0.48
-0.1%
$0.47
$0.40
$7.25
$4.38M0.821.36 million shs144,520 shs
ULURU Inc. stock logo
ULUR
ULURU
$0.00
$0.10
$0.79
$5.35M-3.136,691 shsN/A
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
0.00%-8.55%+3.76%-11.00%-98.48%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00%-0.55%+18.09%+61.71%+1,065.58%
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
0.00%-3.78%+11.73%-63.13%-92.63%
ULURU Inc. stock logo
ULUR
ULURU
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
2.1003 of 5 stars
3.34.00.00.00.00.00.6
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.2893 of 5 stars
0.05.00.00.02.81.70.0
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
1.6772 of 5 stars
3.05.00.00.00.00.00.6
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
2.50
Moderate Buy$25.003,255.25% Upside
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
2.00
Hold$6.001,143.78% Upside
ULURU Inc. stock logo
ULUR
ULURU
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest TOVX, CNSP, SNOA, and ULUR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
Alliance Global Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/8/2025
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/A$5.37 per shareN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$14.29M0.40N/AN/A$2.73 per share1.29
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
N/AN/AN/AN/A$6.85 per shareN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
-$14.86M-$3,748.50N/AN/AN/A-385.41%-193.20%8/13/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$3.100.00N/AN/A-24.23%-58.73%-21.05%8/6/2025 (Estimated)
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
-$25.65M-$33.06N/AN/AN/A-97.50%-55.31%N/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest TOVX, CNSP, SNOA, and ULUR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/17/2025Q4 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.73-$0.15+$0.58-$0.48$4.44 million$3.75 million
5/15/2025Q1 2025
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A-$1.58N/A-$1.58N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
N/AN/AN/AN/AN/A
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
N/A
4.94
4.94
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.09
2.38
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
0.10
1.53
1.53
ULURU Inc. stock logo
ULUR
ULURU
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
14.02%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
6.17%
ULURU Inc. stock logo
ULUR
ULURU
N/A

Insider Ownership

CompanyInsider Ownership
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
0.07%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
24.59%
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
1.46%
ULURU Inc. stock logo
ULUR
ULURU
1.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
CNS Pharmaceuticals, Inc. stock logo
CNSP
CNS Pharmaceuticals
55.46 million5.46 millionNot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.64 million1.24 millionNot Optionable
Theriva Biologics, Inc. stock logo
TOVX
Theriva Biologics
209.06 million8.93 millionNot Optionable
ULURU Inc. stock logo
ULUR
ULURU
230.57 million30.24 millionNot Optionable

Recent News About These Companies

Territory Growth Initiative targets investment and jobs
GPs Honor Indigenous Leadership During NAIDOC Week
Shadows falling across the land
Uluru with friends
Uluru Australia (Mala Walk) Walking Tour

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNS Pharmaceuticals stock logo

CNS Pharmaceuticals NASDAQ:CNSP

$0.75 -0.05 (-6.86%)
Closing price 04:00 PM Eastern
Extended Trading
$0.74 0.00 (-0.42%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.52 -0.07 (-1.95%)
Closing price 04:00 PM Eastern
Extended Trading
$3.58 +0.06 (+1.85%)
As of 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

Theriva Biologics stock logo

Theriva Biologics NYSEAMERICAN:TOVX

$0.48 0.00 (-0.12%)
Closing price 04:10 PM Eastern
Extended Trading
$0.49 +0.01 (+1.16%)
As of 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

ULURU stock logo

ULURU OTCMKTS:ULUR

ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. was founded in 1987 and is based in Addison, Texas.